Truscreen Presentation Videos

NZX Announcement

4 May 2020

TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) has today released three videos
introducing Mrs Victoria Potarina, Chief Executive Officer (CEO), outlining the Company’s
strategy, and the CEO’s thoughts on building a global medical device company.

Video Website Link Website Text Youtube Link
Introduction
Video
https://truscreen.com
/news/video-
introduction-to-
truscreens-ceo-
victoria-potarina/
Get to know TruScreen’s new CEO, Mrs
Victoria Potarina, who joined the
company in March 2020.
Mrs Potarina brings more than twenty
years’ commercial experience, previously
working at Johnson & Johnson (J&J) in
both the UK and across Europe.
In addition, she has held positions at
multiple multinational companies in the
FMCG, over-the-counter, medical devices
and healthcare sectors.
https://www.youtu
be.com/watch?v=5
K86ri95gOc
Growth
Strategy
https://truscreen.com
/news/video-
truscreen-limiteds-
growth-strategy-for-
2020-and-beyond/

TruScreen’s CEO, Mrs. Victoria Potarina,
discusses with Ms Marisa Zammit
TruScreen’s growth strategy and the
pillars that form the foundation of the
strategy.

https://www.youtu
be.com/watch?v=C
lpVNkbWI1I
Building a
Global
Medical
Device
Company
https://truscreen.com
/news/video-building-
a-global-medical-
device-company/

TruScreen CEO, Mrs Victoria Potarina,
discusses what it takes to build a global
medical device company.
Mrs. Potarina speaks to the vital areas
that TruScreen will be investing in and
the company’s priorities as it moves into
the next stage of commercialisation.
https://www.youtu
be.com/watch?v=x
DXHL7ltLi8&t=107s
This announcement has been approved by the Board.

- ENDS -

For more information, visit www.truscreen.com or contact:
TruScreen
Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:
TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/